How a leading academic hospital is analyzing complex clinical data and uncovering new medical insights with powerful precision medicine solution, QIAGEN Clinical Insight. Next-generation sequencing (NGS) creates transformative opportunities to expand our understanding of biomedicine, reshape clinical care, and improve human health. NGS also opens broad vistas for innovation and technology. At the University of […]

Fourth generation Latent TB blood test combines breakthrough CD4/CD8 design for comprehensive immune response detection with the most flexible blood collection workflow Germantown, Maryland, and Hilden, Germany – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) the fourth generation of the market leading blood test […]

ReadCoor and WAVE Life Sciences Initiate Research Collaboration Collaboration aims to unlock next generation stereopure nucleic acid targets with novel FISSEQ technologies Cambridge, Mass. — ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, and WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients […]

Program provides the Only All-in-One Package for Data Collection, Statistical Analysis, Data Visualization, and Publication-Ready Images CFX Maestro is the only real-time PCR instrument software that integrates statistical analysis, data visualization, and publication-ready graphics production in one platform. Hercules, CA — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announces the launch of CFX Maestro Software for CFX […]

Ipswich, MA, USA and Norwich, UK – In its mission to tackle global challenges through life science research, the Earlham Institute (Norwich, UK) faces unique problems raised through the sheer breadth of biological samples that it works with. Samples that the institute processes can come from any number of species of plant, animal, or microbial […]

– Dr. Heikki Lanckriet sole CEO – Peter Llewellyn-Davis proposed for the supervisory board – Pilar de la Huerta to resign from the management board and to transition to the supervisory board Madrid, Spain, and Heidelberg, Germany – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced changes to the management team and supervisory board. […]

NEW YORK and HILDEN, Germany – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  predictive or prognostic tools for  use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment. This will […]

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN’ s NGS panels Hilden, Germany, and Germantown, Maryland – QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received a worldwide license from The Johns Hopkins University for biomarkers that have been shown to play key roles in […]

Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif. & IRVINE, Calif.–Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today jointly announced an agreement to expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint […]